Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.
about
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virusGeneration of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approachSevere acute respiratory syndrome coronavirus as an agent of emerging and reemerging infectionHuman monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutantsStructural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R.Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody.Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particlesBroadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathwayIdentification of a new region of SARS-CoV S protein critical for viral entryProgress towards recombinant anti-infective antibodies.Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirusNeutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technologyCoronavirus antibodies in African bat speciesSubstitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibodyMolecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms.The spike protein of SARS-CoV--a target for vaccine and therapeutic development.Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus.Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitnessEmerging respiratory viruses: challenges and vaccine strategiesReconstitution of the receptor-binding motif of the SARS coronavirus.Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus.Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice.Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirusDevelopment of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.Potential antivirals and antiviral strategies against SARS coronavirus infections.Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions.Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoVStructural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challengeRapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.Chronic beta-AR activation-induced calpain activation and impaired eNOS-Akt signaling mediates cardiac injury in ovariectomized female rats.Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2.Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2.Animal models and vaccines for SARS-CoV infection.Positive reactions on Western blots do not necessarily indicate the epitopes on antigens are continuous.Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses
P2860
Q21128797-A81D463A-B8BA-487C-9CA8-E66F69376155Q24814395-F16BA113-4994-4B52-9A08-0787444B8A2FQ28383088-E8B1779A-11BA-4781-A1D4-81F0E935D413Q28768526-79033D10-B0AB-41D0-88C7-FD354DD3E2E9Q30356663-0D1889EC-0E99-4C43-B0D8-297C39105496Q33239031-7B52ABF2-2B81-46CA-B88A-3D21CE8E2D2CQ33368648-92009B63-5165-4B66-9410-B17826B2FBD5Q33383237-45B1A40E-1093-4538-9B12-6B8D897D47BEQ33512190-4536F292-9148-425A-A234-3354B8C62166Q33568256-F7552A99-0197-4EF2-B3CE-FEC2A38E05E6Q33678943-6DFF5EC4-FD80-4108-B52E-4F20DD0B08CCQ33688229-4F1F7CCF-C592-4DE6-A2B1-09ABECBF0564Q33800892-D6BC41F9-96F2-4BB5-A09D-FC2E6FE20D19Q33897964-C6CA8BD0-6150-4865-B69C-DE19224138F2Q33987404-7FBD71CA-F1FA-4A3B-8B10-113450EBFDB5Q34015988-BBC37FC3-F0F7-42F4-AA99-F0AD8C63D036Q34193942-CFA608BD-7C7C-443F-900F-E2727E4355E9Q34594139-F0ED7F07-216D-4A39-95DF-6895EB70957CQ35070868-6A1974E4-B702-4F76-A236-1C25BD175172Q35815644-CDCEF368-880C-4E77-9AE0-A8A913E5571FQ35857387-0EAA8623-9CEB-4F2E-BD42-71FAA3CE6F9DQ35901171-6B01E863-910D-4642-BDC9-F0C124C238BDQ35914462-235D0DAF-9A1B-4095-BCBC-E51093E317AEQ36154930-A34CDAD4-1DA4-4254-85D7-8AD0FF79894CQ36379337-ECE2323F-262B-45EB-BCA5-0CA6D2D97A6DQ36441511-D4910548-ADCA-4F8A-9BE5-33EE4E2BB645Q36447896-0296DD15-62FF-4EF6-A045-3B8C8ECB9552Q36496355-4468F28B-1B4F-4A2D-8DF4-7593033E32CFQ36498144-6A7746B1-2E0C-4114-A803-5E9C77059134Q36763346-01EF929B-9100-45C7-8FE1-10C3A1AE99ECQ37481314-9F1287F1-2B8C-48A8-B96D-397108A3B4F6Q37486435-F6F46D40-79C8-46DA-A2D6-D06C41D7ABA5Q37929687-73C978BD-3924-47BA-8731-DDA1A304EE21Q40106974-EFA8D67B-C34F-4028-9011-E14EBE5C77CCQ42844863-541AB7BC-6182-4A17-9E7B-E8B0C404F262Q43152086-3FA2112C-7B8C-4BAD-8464-CABEBD34753EQ45201742-14874A5B-C054-4367-A85C-3B2F4F1ED72BQ56552815-0AD3F468-9FDA-430A-8853-DB9AB07FAF63
P2860
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Evaluation of human monoclonal ...... nd analysis of spike variants.
@ast
Evaluation of human monoclonal ...... nd analysis of spike variants.
@en
type
label
Evaluation of human monoclonal ...... nd analysis of spike variants.
@ast
Evaluation of human monoclonal ...... nd analysis of spike variants.
@en
prefLabel
Evaluation of human monoclonal ...... nd analysis of spike variants.
@ast
Evaluation of human monoclonal ...... nd analysis of spike variants.
@en
P2093
P2860
P50
P1433
P1476
Evaluation of human monoclonal ...... nd analysis of spike variants.
@en
P2093
Akikazu Murakami
Leatrice Vogel
Leslie J Matthews
Swee Kee Wong
Wayne A Marasco
P2860
P304
P356
10.1128/JVI.79.10.5900-5906.2005
P577
2005-05-01T00:00:00Z